Akba stock

Ost_Analyst Price Target on AKBA. Based on 3 Wall Street analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. The average price target is $2.00 with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 398.13% change from the last price of $0.40. Over the past three months, the Zacks Consensus Estimate for AKBA's full-year earnings has moved 6.07% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive. According to our latest data, AKBA has moved about 91.93% on a year-to-date basis.Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -29.63% and 39.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock? 8 hours ago · Akebia Therapeutics Trading Down 5.4 %. NASDAQ:AKBA opened at $0.40 on Tuesday. The firm has a market cap of $73.78 million, a price-to-earnings ratio of -0.25 and a beta of 1.49. Jun 29, 2022 · AKBA stock still trades below the $1 mark. Shares of Akebia Therapeutics ( AKBA) stock are up 18% on Wednesday. The kidney therapeutics stock is enjoying this surge on no big news. AKBA stock's ... John P. Butler. Employees: 324. 245 FIRST STREET, SUITE 1100, CAMBRIDGE, MA 02142. 617-871-2098. www.akebia.com. Akebia Therapeutics, Inc. is a biopharmaceutical company which engages in the development of novel proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with ...AKBA Stock Forecast - Get a free AKBA stock predictions and find out whether you should buy or sell AKBA stock. The trend analysis tool will help you make a better prediction on the AKBA stock. Top Penny Stocks: Home: OTC Stocks: Stocks Under $2: Stocks Under $5: NASDAQ Penny Stocks:NAS:AKBA (USA) Manual of Stocks™ Akebia Therapeutics Inc Add to portfolio $ 0.42 -0.0128 (-2.94%) 10:08 PM EST Loading. ... The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.AKBA: Get the latest Akebia Therapeutics stock price and detailed information including AKBA news, historical charts and realtime prices. ... Akebia Therapeutics Inc Stock , AKBA. 0.44-0.01 -2.50% ... This stock may move much during the day (volatility) and with periodic low trading volume this stock is considered to be "high risk". During the last day, the stock moved $0.0269 between high and low, or 6.32%.For the last week the stock has had a daily average volatility of 8.38%.. Our recommended stop-loss: $0.43 (-4.00%) (This stock has high daily movements and this gives high risk.Jul 22, 2022 · In last trading session, Akebia Therapeutics Inc. (NASDAQ:AKBA) saw 2.49 million shares changing hands with its beta currently measuring 1.46. Company’s recent per share price level of $0.44 trading at $0.0 or 0.25% at ring of the bell on the day assigns it a market valuation of $83.79M. AKBA support price is $.41 and resistance is $.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKBA stock will trade within this expected range on the day.Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat.Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 4,000 shares of Akebia's common stock on ...The total value of stock holdings in hedge funds' portfolios went down from $3.1 trillion at the end of December to $2.8 trillion at the end of March. This isn't a terribly large reduction in ...By Amit Chowdhry Today at 9:27 AM. The stock price of Akebia Therapeutics Inc (NASDAQ: AKBA) surged by over 35% pre-market today. This is why. The stock price of Akebia Therapeutics Inc (NASDAQ: AKBA) - a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease - surged by over 35% pre-market today.AKBA / Akebia Therapeutics Inc short borrow fee rates are shown in the following table. This table shows the interest rate that must be paid by a short seller of US:AKBA to the lender of that security. ... Information about the bill, analyst commentary and a popular weed stock with retail investors. Bank Results Weighed on US Stocks Thursday ...Get the latest Akebia Therapeutics Inc. (AKBA) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.8 hours ago · Akebia Therapeutics Trading Down 5.4 %. NASDAQ:AKBA opened at $0.40 on Tuesday. The firm has a market cap of $73.78 million, a price-to-earnings ratio of -0.25 and a beta of 1.49. Jul 01, 2022 · Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat. Jul 14, 2022 · Real-time trade and investing ideas on Akebia Therapeutics Inc. AKBA from the largest community of traders and investors. Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney dis...Find real-time AKBA - Akebia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.Akebia Therapeutics | 29,990 followers on LinkedIn. We're focused on the development & commercialization of therapeutics for people living with kidney disease. | Akebia Therapeutics, Inc. is a ...Jun 28, 2018 · GuruFocus provides stock market research, screener, charts, financial, insider trades, gurus, economic data and value investing tools. prego pasta sauce Akebia to Host Conference Call to Provide Business Update. CAMBRIDGE, Mass., July 26, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30 ...Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Akebia Therapeutics, Inc. ("Akebia" or the "Company") (NASDAQ: AKBA) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired Akebia securities between ...Webull offers kinds of Akebia Therapeutics Inc stock information, including NASDAQ:AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions. By Amit Chowdhry Today at 9:27 AM. The stock price of Akebia Therapeutics Inc (NASDAQ: AKBA) surged by over 35% pre-market today. This is why. The stock price of Akebia Therapeutics Inc (NASDAQ: AKBA) - a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease - surged by over 35% pre-market today.BenzingaAkebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial...AKBA : Akebia Therapeutics stock forecast by Wall Street Analysts. The average Akebia Therapeutics stock forecast from last 6 month is $1.81, and this show a -72.15% decrease in average from the prior price target of the each prediction. Also, this average forecast of $1.81 represents a -81.9% decrease from the past average forecast of $10.0, 6 months ago from 1 wall street analysts.Jul 21, 2022 · Real-time trade and investing ideas on Akebia Therapeutics Inc. AKBA from the largest community of traders and investors. Jul 12, 2022 · AKBA support price is $.38 and resistance is $.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKBA stock will trade within this expected range on the day. John P. Butler. Employees: 324. 245 FIRST STREET, SUITE 1100, CAMBRIDGE, MA 02142. 617-871-2098. www.akebia.com. Akebia Therapeutics, Inc. is a biopharmaceutical company which engages in the development of novel proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with ...CONTRAINDICATION. AURYXIA ® (ferric citrate) is contraindicated in patients with iron overload syndromes, e.g., hemochromatosis. WARNINGS AND PRECAUTIONS. Iron Overload: Increases in serum ferritin and transferrin saturation (TSAT) were observed in clinical trials with AURYXIA in patients with chronic kidney disease (CKD) on dialysis treated for hyperphosphatemia, which may lead to excessive ...PR Newswire -8.01%. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic ...Jul 21, 2022 · Share Market Snapshot. Stock Gestures. Trading Guidance About the Akebia Therapeutics, Inc. stock forecast. As of 2022 June 29, Wednesday current price of AKBA stock is 0.351$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Akebia Therapeutics stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given period.Akebia Therapeutics, Inc. has a 12-month low of $0.30 and a 12-month high of $4.33. The company has a market capitalization of $64.44 million, a price-to-earnings ratio of -0.22 and a beta of 1.57 ...Akebia Therapeutics Inc (US:AKBA) has 319 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 89,960,275 shares. Largest shareholders include Vanguard Group Inc, BlackRock Inc., State Street Corp, XBI - SPDR(R) S&P(R) Biotech ETF, VTSMX ...Analysts who follow Akebia Therapeutics Inc ( AKBA) on average expect it to add 346.29% over the next twelve months. Those same analysts give the stock an average rating of Hold. That average rating earns the stock an Analyst Ranking of 3, which means it ranks higher than 3 of stocks, based on data compiled by InvestorsObserver .AKBA News: Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka. 06/30/2022 04:05:00 PM. AKBA News: Current Report Filing (8-k) 06/10/2022 08:01:41 AM. AKBA News: Statement of Changes in Beneficial Ownership (4)8 hours ago · Akebia Therapeutics Trading Down 5.4 %. NASDAQ:AKBA opened at $0.40 on Tuesday. The firm has a market cap of $73.78 million, a price-to-earnings ratio of -0.25 and a beta of 1.49. extended stay hotels seattle Jul 19, 2022 · Learn about Akebia Therapeutics Inc (AKBA:XNAS) stock quote with Morningstar's rating and analysis and stay up to date with the current news, price, valuation, dividends and other stock ... The low in the last 52 weeks of Akebia Therapeutics stock was 0.30. According to the current price, Akebia Therapeutics is 147.25% away from the 52-week low. What was the 52-week high for Akebia...For starters, Akebia isn't new to the spotlight. The stock was trading around $20 a share back in 2017. It's far from those numbers in 2022, but most companies are feeling the affects of the current economy and recession fears. Akebia is trading around $0.40 at the moment with a 52-week high of $4.33.Real time Akebia Therapeutics (AKBA) stock price quote, stock graph, news & analysis. Akebia Therapeutics Inc. Annual stock financials by MarketWatch. View the latest AKBA financial statements, income statements and financial ratios.Webull offers AKBA Ent Holdg (AKBA) historical stock prices, in-depth market analysis, NASDAQ: AKBA real-time stock quote data, in-depth charts, and a fully built financial calendar to help you invest smart. Buy AKBA fractional shares at Webull.Institutions like mutual funds, pensions, and investment banks typically have large volumes of capital that they use to invest in stocks. Since institutions are tasked with maximizing returns for their investors, they typically spend a lot of time and effort understanding the company's revenue and profit prospects before they invest. Pre-Market Trades. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as ... Jul 21, 2022 · Share Market Snapshot. Stock Gestures. Trading Guidance Analyst Price Target on AKBA. Based on 3 Wall Street analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. The average price target is $2.00 with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 398.13% change from the last price of $0.40. Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat.Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat.Webull offers AKBA Ent Holdg (AKBA) historical stock prices, in-depth market analysis, NASDAQ: AKBA real-time stock quote data, in-depth charts, and a fully built financial calendar to help you invest smart. Buy AKBA fractional shares at Webull.Jul 15, 2022 · A high-level overview of Akebia Therapeutics, Inc. (AKBA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. AKBA | Akebia Therapeutics to Report Second Quarter Financial Results... AKBA support price is $.41 and resistance is $.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKBA stock will trade within this expected range on the day.AKBA Stock Trend. The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -7.82% during the next 3 months and, with a 90% probability hold a price between $0.27 and $0.42 at the end of this 3-month period.Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat.8 hours ago · Akebia Therapeutics Trading Down 5.4 %. NASDAQ:AKBA opened at $0.40 on Tuesday. The firm has a market cap of $73.78 million, a price-to-earnings ratio of -0.25 and a beta of 1.49. NAS:AKBA (USA) Manual of Stocks™ Akebia Therapeutics Inc Add to portfolio $ 0.42 -0.0128 (-2.94%) 10:08 PM EST Loading. ... The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.Options chains for selling calls and puts, for symbol AKBA, from Stock Options Channel. Home: Articles: Selling Calls For Income: Selling Puts For Income: Top Ideas: My Watchlist: YieldBoost Ranks: ... AKBA — Performance: Akebia Therapeutics Inc (AKBA) Last: 0.425, Change: -0.0181 (-4.08%), Volume: 2.52M Put volume: 55 ...Jul 21, 2022 · Real-time trade and investing ideas on Akebia Therapeutics Inc. AKBA from the largest community of traders and investors. Find real-time AKBA - Akebia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney dis...Akebia Therapeutics Inc (NASDAQ: AKBA) and Otsuka Holdings (OTC: OTSKY) separately announced to call for licensing and co-development agreement for vadadustat. Otsuka sent a written notice to ... Akebia Therapeutics | 29,990 followers on LinkedIn. We're focused on the development & commercialization of therapeutics for people living with kidney disease. | Akebia Therapeutics, Inc. is a ...Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -29.63% and 39.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Jul 15, 2022 · A high-level overview of Akebia Therapeutics, Inc. (AKBA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. The options have an exercise price of $0.35 per share, which is equal to the closing price of Akebia's common stock on the grant date. About Akebia Therapeutics ( AKBA ) Akebia Therapeutics ( AKBA ), Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.AKBA | Akebia Therapeutics to Report Second Quarter Financial Results...Jun 30, 2022 · Akebia to Host Conference Call to Provide Business Update. CAMBRIDGE, Mass., July 26, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30 ... Find out which Guru investors are buying and selling Akebia Therapeutics Inc (AKBA) today. Get the latest info and news about AKBA stock at GuruFocus.com Get Your 7-Day Free Trial!Jul 26, 2022 · Plus, the 36-month beta value for AKBA is at 1.54. Opinions of the stock are interesting as 0 analysts out of 4 who provided ratings for Akebia Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 3 rated it as “hold,” and 1 as “sell.” About Akebia Therapeutics, Inc. 245 FIRST STREET SUITE 1100, CAMBRIDGE, Massachusetts, 2142, United States +1 617 871-2098 https://www.akebia.com Akebia Therapeutics Inc is a biopharmaceutical...The low in the last 52 weeks of Akebia Therapeutics stock was 0.30. According to the current price, Akebia Therapeutics is 147.25% away from the 52-week low. What was the 52-week high for Akebia...Box: Pts ATR Field: High/Low Close. Reversal: Pts % ATR Field: High/Low Close. Size. 360 460 520 620 700 780 900 Portrait Landscape. Width: Height: Color Scheme. Default Blue Blue Gray Color Vision Impaired Dark Amber Dark Blue Dark Gray Dark Green Ice Graphite Mint Mohave Monochrome (Print) Murphy Night Rainier Rose Sand Sea Green Solar Spruce ... For starters, Akebia isn't new to the spotlight. The stock was trading around $20 a share back in 2017. It's far from those numbers in 2022, but most companies are feeling the affects of the current economy and recession fears. Akebia is trading around $0.40 at the moment with a 52-week high of $4.33.Akebia Therapeutics Inc. Annual stock financials by MarketWatch. View the latest AKBA financial statements, income statements and financial ratios. Box: Pts ATR Field: High/Low Close. Reversal: Pts % ATR Field: High/Low Close. Size. 360 460 520 620 700 780 900 Portrait Landscape. Width: Height: Color Scheme. Default Blue Blue Gray Color Vision Impaired Dark Amber Dark Blue Dark Gray Dark Green Ice Graphite Mint Mohave Monochrome (Print) Murphy Night Rainier Rose Sand Sea Green Solar Spruce ... Pre-Market Trades. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as ... View institutional stock ownership, mutual fund ownership, and top individual ownership of AKEBIA THERAPEUTICS, INC. (AKBA).AKBA | Akebia Therapeutics to Report Second Quarter Financial Results...A high-level overview of Akebia Therapeutics, Inc. (AKBA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.AKBA Price Action: Akebia has a 52-week high of $4.09 and a 52-week low of 30 cents. The stock was up 41.9% in after hours at 51 cents at press time, according to Benzinga Pro .AKBA stock returns are also predicted based on historical data. According to our research, AKBA stock is a bad long-term investment. AKBA share price has been in a bear cycle for the past year. Akebia Therapeutics, Inc. stock trend is negative. Akebia Therapeutics company info.AKBA updated stock price target summary. Dow Jones, a News Corp company About WSJ. News Corp is a global, diversified media and information services company focused on creating and distributing ...Complete Akebia Therapeutics Inc. stock information by Barron's. View real-time AKBA stock price and news, along with industry-best analysis.Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA)... Zoetis (ZTS) delivered earnings and revenue surprises of 8.20% and 0.88%, respectively, for the quarter ended March 2022. Akebia to Host Conference Call to Provide Business Update. CAMBRIDGE, Mass., July 26, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30 ... seattle craigslist cars by owner WWR Stock. Akebia Therapeutics Inc. (AKBA) shares have dropped -14.35% to $0.71 in Thursday's early session. Akebia Therapeutics (AKBA) stock finished last trading session at $0.83. The stock recorded a trading volume of 5.57 million shares, which is below the average daily trading volume published for the last 50 days of 6.22 million shares.Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial...Go To: Price Overview Performance Report Interactive Chart Snapshot Chart Barchart Opinion Trading Strategies Top Trade Alerts Technical Analysis Trader's Cheat Sheet Price History Historical Data Options Prices Volatility & Greeks Options Overview History Unusual Options Activity Put/Call Ratios Covered Calls Naked Puts Credit & Debit Spreads ...Go To: Price Overview Performance Report Interactive Chart Snapshot Chart Barchart Opinion Trading Strategies Top Trade Alerts Technical Analysis Trader's Cheat Sheet Price History Historical Data Options Prices Volatility & Greeks Options Overview History Unusual Options Activity Put/Call Ratios Covered Calls Naked Puts Credit & Debit Spreads ...Akebia Therapeutics Trading Down 5.4 %. NASDAQ:AKBA opened at $0.40 on Tuesday. The firm has a market cap of $73.78 million, a price-to-earnings ratio of -0.25 and a beta of 1.49.Mar 31, 2022 · Cantor Fitzgerald has set a price target of $1 in its downgrade of Akebia (AKBA) to neutral from overweight. The average price target for the stock stands at $7.00 per share on Wall Street, currently. Jul 12, 2022 · Analyst Forecast. According to 10 analysts, the average rating for AKBA stock is "Sell." The 12-month stock price forecast is 1.66, which is an increase of 269.05% from the latest price. HIVE | HIVE Achieves Record Annual Revenue Ended March 31, 2022 of $211 Million and Earnings of $79 Million with a 545% Growth in BTC Mining Hashrate.PR Newswire -8.01%. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic ...AKBA's average broker recommendation rating improved by 0.29 over the prior 52 weeks. The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors. AKBA has a greater average analyst price target than 22.19% of all US stocks. Real-time trade and investing ideas on Akebia Therapeutics Inc. AKBA from the largest community of traders and investors. Rooms Shows Rankings Earnings Newsletters Shop. Cancel. Log In. Sign Up. DOW 0.00%. S&P 500 0.00%. NASDAQ 0.00%. Trending now. Akebia Therapeutics Inc. 0.43 0.02 (4.09%) Watch.Jul 22, 2022 · In last trading session, Akebia Therapeutics Inc. (NASDAQ:AKBA) saw 2.49 million shares changing hands with its beta currently measuring 1.46. Company’s recent per share price level of $0.44 trading at $0.0 or 0.25% at ring of the bell on the day assigns it a market valuation of $83.79M. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 4,000 shares of Akebia's common stock on ...#AKBA #AKBASTOCK #AKBAstockanalysis #akbastockprediction #AkebiaTherapeutics #nyse #nasdaq #dowjones #stocksAKBA Stock - Akebia Therapeutics Inc Stock Breaki...AKBA's average broker recommendation rating improved by 0.29 over the prior 52 weeks. The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors. AKBA has a greater average analyst price target than 22.19% of all US stocks. On 2022-07-01, Akebia Therapeutics (AKBA-Q) stock closed at a price of $0.389. Featured Portfolios The Daily Top Stock Picks Top 25 Experts Buzzing Stocks Panic-Proof Portfolio The Monthly Gems. Advertising AdvertisingCAMBRIDGE, Mass., June 30, 2022 /PRNewswire/ -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has executed an agreement to terminate the U.S. and ex-U.S. vadadustat Collaboration and License Agreements with Otsuka ...Real-time trade and investing ideas on Akebia Therapeutics Inc. AKBA from the largest community of traders and investors. Rooms Shows Rankings Earnings Newsletters Shop. Cancel. Log In. Sign Up. DOW 0.00%. S&P 500 0.00%. NASDAQ 0.00%. Trending now. Akebia Therapeutics Inc. 0.40 0.02 (4.84%) Watch.NAS:AKBA (USA) Manual of Stocks™ Akebia Therapeutics Inc Add to portfolio $ 0.42 -0.0128 (-2.94%) 10:08 PM EST Loading. ... The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.Find real-time AKBA - Akebia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat.Box: Pts ATR Field: High/Low Close. Reversal: Pts % ATR Field: High/Low Close. Size. 360 460 520 620 700 780 900 Portrait Landscape. Width: Height: Color Scheme. Default Blue Blue Gray Color Vision Impaired Dark Amber Dark Blue Dark Gray Dark Green Ice Graphite Mint Mohave Monochrome (Print) Murphy Night Rainier Rose Sand Sea Green Solar Spruce ... Akebia Therapeutics (AKBA) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more. 20/07/2022 12:44:22 1-888-992-3836 Free ...Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -29.63% and 39.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?Akebia Therapeutics (AKBA) soared more than 25% on Monday on high volume after UBS initiated coverage on the biopharmaceutical company with a "buy" rating and $28 price target.Jul 25, 2022 · Today, Akebia Therapeutics Inc. (NASDAQ:AKBA) was down $0.023 to close Monday at $0.40. The company opened at $0.42 and shares fluctuated between $0.43 and $0.40 with 3,485,654 shares trading ... We are a fully integrated biopharmaceutical company. Our team works to address complications of kidney disease. We have both a commercially available medicine and a late stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vadadustat.Vadadustat and other HIF-PHIs are based on Nobel Prize-winning science.Institutions like mutual funds, pensions, and investment banks typically have large volumes of capital that they use to invest in stocks. Since institutions are tasked with maximizing returns for their investors, they typically spend a lot of time and effort understanding the company's revenue and profit prospects before they invest. The all-time high Akebia Therapeutics stock closing price was 29.17 on June 20, 2014. The Akebia Therapeutics 52-week high stock price is 3.63, which is 706.7% above the current share price. The Akebia Therapeutics 52-week low stock price is 0.30, which is 33.3% below the current share price. The average Akebia Therapeutics stock price for the ...John P. Butler. Employees: 324. 245 FIRST STREET, SUITE 1100, CAMBRIDGE, MA 02142. 617-871-2098. www.akebia.com. Akebia Therapeutics, Inc. is a biopharmaceutical company which engages in the development of novel proprietary therapeutics based on hypoxia-inducible factor biology and the commercialization of these products for patients with ...Looking for a break above 5.11. Stop signal 4.31. First target 6.43 , Second target momentum.Akebia Therapeutics (AKBA) soared more than 25% on Monday on high volume after UBS initiated coverage on the biopharmaceutical company with a "buy" rating and $28 price target.Jul 25, 2022 · According to analyst projections, AKBA’s forecast low is $1.25 with $2.00 as the target high. To hit the forecast high, the stock’s price needs a -365.12% plunge from its current level, while the stock would need to soar -190.7% for it to hit the projected low. Akebia Therapeutics Inc. (AKBA) estimates and forecasts AKBA support price is $.41 and resistance is $.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKBA stock will trade within this expected range on the day.According to analyst projections, AKBA's forecast low is $1.25 with $2.00 as the target high. To hit the forecast high, the stock's price needs a -365.12% plunge from its current level, while the stock would need to soar -190.7% for it to hit the projected low. Akebia Therapeutics Inc. (AKBA) estimates and forecastsJul 15, 2022 · A high-level overview of Akebia Therapeutics, Inc. (AKBA) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Akebia Therapeutics, Inc. is a company in the U.S. stock market and it is a holding in 47 U.S.-traded ETFs. AKBA has around 22.2M shares in the U.S. ETF market.Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impactedAkebia Therapeutics Inc. Institutional investors purchased a net $11.9 million shares of AKBA during the quarter ended June 2019 and now own 45.84% of the total shares outstanding. This is a ...The volatility of a stock over a given time period. It is calculated by determining the average standard deviation from the average price of the stock over one month or 21 business days. Historical volatility can be compared with implied volatility to determine if a stock's options are over- or undervalued.Akebia Therapeutics (AKBA) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more. 10/07/2022 04:52:46 1-888-992-3836 Free ...Box: Pts ATR Field: High/Low Close. Reversal: Pts % ATR Field: High/Low Close. Size. 360 460 520 620 700 780 900 Portrait Landscape. Width: Height: Color Scheme. Default Blue Blue Gray Color Vision Impaired Dark Amber Dark Blue Dark Gray Dark Green Ice Graphite Mint Mohave Monochrome (Print) Murphy Night Rainier Rose Sand Sea Green Solar Spruce ... The volatility of a stock over a given time period. It is calculated by determining the average standard deviation from the average price of the stock over one month or 21 business days. Historical volatility can be compared with implied volatility to determine if a stock's options are over- or undervalued.The total value of stock holdings in hedge funds' portfolios went down from $3.1 trillion at the end of December to $2.8 trillion at the end of March. This isn't a terribly large reduction in ...The total value of stock holdings in hedge funds' portfolios went down from $3.1 trillion at the end of December to $2.8 trillion at the end of March. This isn't a terribly large reduction in ...Find the latest Akebia Therapeutics, Inc. (AKBA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Akebia Therapeutics, Inc. is incorporated in the state of Delaware. Akebia Therapeutics, Inc is primarely in the business of pharmaceutical preparations. For financial reporting, their fiscal year ends on December 31st. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K ...Dec 29, 2021 · AKBA 4HR. AKBA. , 240 Long. TechnicallyCorrect Jun 21, 2021. NASDAQ:AKBA 4HR chart is setting up a nice buy signal. It has a very large rounded base followed by a trendline break. Additionally, the 50 EMA is about to cross above the 200 EMA. 2. 0. Jun 29, 2022 · AKBA stock still trades below the $1 mark. Shares of Akebia Therapeutics ( AKBA) stock are up 18% on Wednesday. The kidney therapeutics stock is enjoying this surge on no big news. AKBA stock's ... Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -29.63% and 39.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock? Jul 25, 2022 · According to analyst projections, AKBA’s forecast low is $1.25 with $2.00 as the target high. To hit the forecast high, the stock’s price needs a -365.12% plunge from its current level, while the stock would need to soar -190.7% for it to hit the projected low. Akebia Therapeutics Inc. (AKBA) estimates and forecasts AKBA stock returns are also predicted based on historical data. According to our research, AKBA stock is a bad long-term investment. AKBA share price has been in a bear cycle for the past year. Akebia Therapeutics, Inc. stock trend is negative. Akebia Therapeutics company info.Analyst Price Target on AKBA. Based on 3 Wall Street analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. The average price target is $2.00 with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 398.13% change from the last price of $0.40. PR Newswire. SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Akebia Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 13, 2022 - (NASDAQ: AKBA ...Featured Post From StockTwits About AKBA Will post Telegram to join my team once posts complete, follow and don't miss out! Have a blessed weekend!CAMBRIDGE, Mass., June 30, 2022 /PRNewswire/ -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it has executed an agreement to terminate the U.S. and ex-U.S. vadadustat Collaboration and License Agreements with Otsuka ...PR Newswire -8.01%. Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic ...View institutional stock ownership, mutual fund ownership, and top individual ownership of AKEBIA THERAPEUTICS, INC. (AKBA).View institutional stock ownership, mutual fund ownership, and top individual ownership of AKEBIA THERAPEUTICS, INC. (AKBA).AKBA | Akebia Therapeutics to Report Second Quarter Financial Results... Dec 29, 2021 · AKBA 4HR. AKBA. , 240 Long. TechnicallyCorrect Jun 21, 2021. NASDAQ:AKBA 4HR chart is setting up a nice buy signal. It has a very large rounded base followed by a trendline break. Additionally, the 50 EMA is about to cross above the 200 EMA. 2. 0. Real-time trade and investing ideas on Akebia Therapeutics Inc. AKBA from the largest community of traders and investors. Rooms Shows Rankings Earnings Newsletters Shop. Cancel. Log In. Sign Up. DOW 0.00%. S&P 500 0.00%. NASDAQ 0.00%. Trending now. Akebia Therapeutics Inc. 0.40 0.02 (4.84%) Watch.Jul 22, 2022 · In last trading session, Akebia Therapeutics Inc. (NASDAQ:AKBA) saw 2.49 million shares changing hands with its beta currently measuring 1.46. Company’s recent per share price level of $0.44 trading at $0.0 or 0.25% at ring of the bell on the day assigns it a market valuation of $83.79M. Jul 25, 2022 · According to analyst projections, AKBA’s forecast low is $1.25 with $2.00 as the target high. To hit the forecast high, the stock’s price needs a -365.12% plunge from its current level, while the stock would need to soar -190.7% for it to hit the projected low. Akebia Therapeutics Inc. (AKBA) estimates and forecasts The all-time high Akebia Therapeutics stock closing price was 29.17 on June 20, 2014. The Akebia Therapeutics 52-week high stock price is 3.63, which is 706.7% above the current share price. The Akebia Therapeutics 52-week low stock price is 0.30, which is 33.3% below the current share price. The average Akebia Therapeutics stock price for the ...Hello everyone, this is the first issue of The Biotech Report! In this issue of The Biotech Report, we will thoroughly examine Akebia Therapeutics: its partnerships, CEO, insider trading patterns, institutional holdings, and financials. candle making supplies perth Webull offers kinds of Akebia Therapeutics Inc stock information, including NASDAQ:AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 4,000 shares of Akebia's common stock on ...Jul 25, 2022 · Today, Akebia Therapeutics Inc. (NASDAQ:AKBA) was down $0.023 to close Monday at $0.40. The company opened at $0.42 and shares fluctuated between $0.43 and $0.40 with 3,485,654 shares trading ... Looking for a break above 5.11. Stop signal 4.31. First target 6.43 , Second target momentum.Jun 30, 2022 · Akebia to Host Conference Call to Provide Business Update. CAMBRIDGE, Mass., July 26, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30 ... Jun 30, 2022 · Akebia to Host Conference Call to Provide Business Update. CAMBRIDGE, Mass., July 26, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30 ... The shares of Akebia Therapeutics Inc (NASDAQ: AKBA) have received a $7 price target from Needham & Company. These are the details. The shares of Akebia Therapeutics Inc (NASDAQ: AKBA) have received a $7 price target from Needham & Company. And Needham & Company analyst Serge Belanger reiterated a "Buy" rating on the shares.Akebia Therapeutics | 29,990 followers on LinkedIn. We're focused on the development & commercialization of therapeutics for people living with kidney disease. | Akebia Therapeutics, Inc. is a ...Akebia Therapeutics Inc (NAS:AKBA) *12-month growth rate is calculated with the quarterly per share revenue (EBITDA, FCF, earnings) of the last 12 months over the per share revenue (EBITDA, FCF, earnings) over the previous 12 months. 5-year and 10-year growth rates are calculated with least-square regression based on the 6-year and 11-year ...View Akebia Therapeutics, Inc AKBA investment & stock information. Get the latest Akebia Therapeutics, Inc AKBA detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl ...Webull offers AKBA Ent Holdg (AKBA) historical stock prices, in-depth market analysis, NASDAQ: AKBA real-time stock quote data, in-depth charts, and a fully built financial calendar to help you invest smart. Buy AKBA fractional shares at Webull. new air wine cooler Go To: Price Overview Performance Report Interactive Chart Snapshot Chart Barchart Opinion Trading Strategies Top Trade Alerts Technical Analysis Trader's Cheat Sheet Price History Historical Data Options Prices Volatility & Greeks Options Overview History Unusual Options Activity Put/Call Ratios Covered Calls Naked Puts Credit & Debit Spreads ...The volatility of a stock over a given time period. It is calculated by determining the average standard deviation from the average price of the stock over one month or 21 business days. Historical volatility can be compared with implied volatility to determine if a stock's options are over- or undervalued.AKBA News: Akebia Therapeutics Regaining Rights to Vadadustat in the United States, Europe, China and Access Consortium Countries upon Termination of Collaboration and License Agreements with Otsuka. 06/30/2022 04:05:00 PM. AKBA News: Current Report Filing (8-k) 06/10/2022 08:01:41 AM. AKBA News: Statement of Changes in Beneficial Ownership (4)AKBA : Akebia Therapeutics stock forecast by Wall Street Analysts. The average Akebia Therapeutics stock forecast from last 6 month is $1.81, and this show a -72.15% decrease in average from the prior price target of the each prediction. Also, this average forecast of $1.81 represents a -81.9% decrease from the past average forecast of $10.0, 6 months ago from 1 wall street analysts.8 hours ago · Akebia Therapeutics Trading Down 5.4 %. NASDAQ:AKBA opened at $0.40 on Tuesday. The firm has a market cap of $73.78 million, a price-to-earnings ratio of -0.25 and a beta of 1.49. Akebia Therapeutics Inc. Institutional investors purchased a net $11.9 million shares of AKBA during the quarter ended June 2019 and now own 45.84% of the total shares outstanding. This is a ...Jul 21, 2022 · Share Market Snapshot. Stock Gestures. Trading Guidance Akebia Therapeutics (AKBA) Reports Q1 Loss, Tops Revenue Estimates. Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of -29.63% and 39.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock? It is currently valued at $1.56. When the transactions were called off in the previous session, Stock hit the highs of $1.66, after setting-off with the price of $1.66. Company's stock value dipped to $1.54 during the trading on the day. When the trading was stopped its value was $1.65.Recently in News on July 6, 2022, Selecta Biosciences to ...Jul 18, 2022 · Their AKBA stock forecasts range from $1.25 to $2.00. On average, they predict Akebia Therapeutics' stock price to reach $1.75 in the next year. This suggests a possible upside of 280.2% from the stock's current price. View analysts' price targets for Akebia Therapeutics or view top-rated stocks among Wall Street analysts. Akebia Therapeutics, Inc. (AKBA) Performance Graph for POWR Ratings Akebia Therapeutics, Inc. (AKBA) Interactive Chart AKBA Chart by TradingViewTheir AKBA stock forecasts range from $1.25 to $2.00. On average, they predict Akebia Therapeutics' share price to reach $1.75 in the next year. This suggests a possible upside of 335.9% from the stock's current price. View analysts' price targets for Akebia Therapeutics or view top-rated stocks among Wall Street analysts.Jun 29, 2022 · AKBA stock climbed nearly 40% in the past week and also surged more than 50% in pre-market today. And this comes after the stock market suffered major losses in the previous 24-hours. The end of June has been very volatile. A market rally was quickly followed by a bearish signal and dropping stock prices. Jun 28, 2018 · GuruFocus provides stock market research, screener, charts, financial, insider trades, gurus, economic data and value investing tools. 8 hours ago · Akebia Therapeutics Stock Performance. NASDAQ AKBA opened at $0.40 on Tuesday. The firm has a 50 day simple moving average of $0.39 and a 200-day simple moving average of $1.14. Akebia Therapeutics Inc. advanced stock charts by MarketWatch. View AKBA historial stock data and compare to other stocks and exchanges.Purity & Documentation. AKBA (Acetyl-11-keto-β-boswellic acid) is an active triterpenoid compound from the extract of Boswellia serrate and a novel Nrf2 activator. AKBA (Acetyl-11-keto-β-boswellic acid) significantly reduced infarct volumes and apoptotic cells, and also increased neurologic scores by elevating the Nrf2 and HO-1 expression in ...Jun 29, 2022 · AKBA stock still trades below the $1 mark. Shares of Akebia Therapeutics ( AKBA) stock are up 18% on Wednesday. The kidney therapeutics stock is enjoying this surge on no big news. AKBA stock's ... Real-time trade and investing ideas on Akebia Therapeutics Inc. AKBA from the largest community of traders and investors. Rooms Shows Rankings Earnings Newsletters Shop. Cancel. Log In. Sign Up. DOW 0.00%. S&P 500 0.00%. NASDAQ 0.00%. Trending now. Akebia Therapeutics Inc. 0.40 0.02 (4.84%) Watch.Find real-time AKBA - Akebia Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.8 hours ago · Akebia Therapeutics Stock Performance. NASDAQ AKBA opened at $0.40 on Tuesday. The firm has a 50 day simple moving average of $0.39 and a 200-day simple moving average of $1.14. Akebia Therapeutics (AKBA) stock price, charts, trades & the US's most popular discussion forums. Free forex prices, toplists, indices and lots more. 20/07/2022 12:44:22 1-888-992-3836 Free ...AKBA earnings call for the period ending June 30, 2021. ... Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as ...AKBA stock forecast Our latest prediction for Akebia Therapeutics Inc.'s stock price was made on the March 1, 2022 when the stock price was at 2.15$.. In the short term (2weeks), AKBA's stock price should outperform the market by 1.69%.During that period the price should oscillate between -10.67% and +17.75%.. In the medium term (3months), AKBA's stock price should outperform the market by 0.24%.Pre-Market Trades. Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as ... Cantor Fitzgerald has set a price target of $1 in its downgrade of Akebia (AKBA) to neutral from overweight. The average price target for the stock stands at $7.00 per share on Wall Street, currently.Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The firm is also involved in the development and commercialization of drugs for the treatment of renal and metabolic disorders. Its products include Auryxia and Vadadustat.Stock split history for Akebia Therapeutics since 2022. Prices shown are actual historical values and are not adjusted for either splits or dividends. Please see the "Historical Prices" tab for adjusted price values.Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Akebia Therapeutics, Inc. (“Akebia” or the “Company”) (NASDAQ: AKBA)... Zoetis (ZTS) delivered earnings and revenue surprises of 8.20% and 0.88%, respectively, for the quarter ended March 2022. Because Finexy believes that no individual model can accurately predict the future direction of the price of a stock, we average buy and sell signals across multiple forward and backward looking indicators to determine whether the price is likely to go up or down over the short term. Akebia Therapeutics, Inc. (NASDAQ: AKBA) stock price is $0.32 as of the last check on Monday, May 23. During the trading session, AKBA stock reached the peak price of $0.34 while $0.31 was the lowest point it dropped to.AKBA's average broker recommendation rating improved by 0.29 over the prior 52 weeks. The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors. AKBA has a greater average analyst price target than 22.19% of all US stocks. Akebia Therapeutics (AKBA) stock is dropping late Tuesday afternoon after the company reported its 2015 fourth quarter results after yesterday's market close.Below, we examine the compound annual growth rate — CAGR for short — of an investment into Akebia Therapeutics shares, starting with a $10,000 purchase of AKBA, presented on a split-history-adjusted basis factoring in the complete Akebia Therapeutics stock split history. Growth of $10,000.00. Without Dividends Reinvested. Start date: 03/21 ...In depth view into AKBA (Akebia Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. ... (AKBA) Shareholders of Class Action Final Deadline and Last Few Hours to Actively Participate. Globe Newswire. 05/13 10:32. AKBA SHAREHOLDER ALERT: Jakubowitz Law Reminds Akebia Shareholders of a Lead ...Only 13 left in stock - order soon. Vitacost Synergy 5-Loxin®-AKBA Boswellia Extract -- 150 mg per serving - 120 Capsules. 120 Count (Pack of 1) 4.1 out of 5 stars 115. ... Ontologix: Boswellia with AKBA - Dietary Supplement for Joint Health Support, Digestive Function and Balanced Immune Response - 120 Capsules - 500mg Boswellia Serrata ...For starters, Akebia isn't new to the spotlight. The stock was trading around $20 a share back in 2017. It's far from those numbers in 2022, but most companies are feeling the affects of the current economy and recession fears. Akebia is trading around $0.40 at the moment with a 52-week high of $4.33.Real-time trade and investing ideas on Akebia Therapeutics Inc. AKBA from the largest community of traders and investors. Rooms Shows Rankings Earnings Newsletters Shop. Cancel. Log In. Sign Up. DOW 0.00%. S&P 500 0.00%. NASDAQ 0.00%. Trending now. Akebia Therapeutics Inc. 0.43 0.02 (4.09%) Watch.Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately. AKBA: 7.04 (-3.16%) Corporate Donations to Support AKF Coronavirus Emergency Fund Help Provide a Lifeline to Low-Income Kidney Patients ACCESSWIRE - Tue Mar 31, 3:41PM CDT.Jul 25, 2022 · Today, Akebia Therapeutics Inc. (NASDAQ:AKBA) was down $0.023 to close Monday at $0.40. The company opened at $0.42 and shares fluctuated between $0.43 and $0.40 with 3,485,654 shares trading ... It is currently valued at $1.56. When the transactions were called off in the previous session, Stock hit the highs of $1.66, after setting-off with the price of $1.66. Company's stock value dipped to $1.54 during the trading on the day. When the trading was stopped its value was $1.65.Recently in News on July 6, 2022, Selecta Biosciences to ...By Amit Chowdhry Today at 9:27 AM. The stock price of Akebia Therapeutics Inc (NASDAQ: AKBA) surged by over 35% pre-market today. This is why. The stock price of Akebia Therapeutics Inc (NASDAQ: AKBA) - a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease - surged by over 35% pre-market today.Akebia Therapeutics Price Performance. AKBA stock opened at $0.42 on Friday. The company has a 50 day simple moving average of $0.38 and a 200 day simple moving average of $1.24.Acquiring of stock options Automatic Buy Plan on file to periodically buy shares with no regard for market condition Automatic Sell ... This chart summarizes weekly insider transactions for AKBA for the last 12 months. Each bar in the chart represents activity for that week. Mouseover each for details, or view this data in table format in the ...Analyst Price Target on AKBA. Based on 3 Wall Street analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. The average price target is $2.00 with a high forecast of $2.00 and a low forecast of $2.00. The average price target represents a 398.13% change from the last price of $0.40. AKBA support price is $.41 and resistance is $.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKBA stock will trade within this expected range on the day.Akebia Therapeutics Inc. (NASDAQ:AKBA) price closed lower on Monday, July 25, dropping -5.41% below its previous close. A look at the daily price movement shows that the last close reads $0.43, with intraday deals fluctuated between $0.396 and $0.4294. The company's 5Y monthly beta was ticking 1.33.Jul 22, 2022 · In last trading session, Akebia Therapeutics Inc. (NASDAQ:AKBA) saw 2.49 million shares changing hands with its beta currently measuring 1.46. Company’s recent per share price level of $0.44 trading at $0.0 or 0.25% at ring of the bell on the day assigns it a market valuation of $83.79M. AKBA's average broker recommendation rating improved by 0.29 over the prior 52 weeks. The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors. AKBA has a greater average analyst price target than 22.19% of all US stocks.Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial ...AKBA / Akebia Therapeutics Inc short borrow fee rates are shown in the following table. This table shows the interest rate that must be paid by a short seller of US:AKBA to the lender of that security. ... Information about the bill, analyst commentary and a popular weed stock with retail investors. Bank Results Weighed on US Stocks Thursday ...Akebia Therapeutics Price Performance. AKBA stock opened at $0.42 on Friday. The company has a 50 day simple moving average of $0.38 and a 200 day simple moving average of $1.24.AKBA stock forecast Our latest prediction for Akebia Therapeutics Inc.'s stock price was made on the March 1, 2022 when the stock price was at 2.15$.. In the short term (2weeks), AKBA's stock price should outperform the market by 1.69%.During that period the price should oscillate between -10.67% and +17.75%.. In the medium term (3months), AKBA's stock price should outperform the market by 0.24%.Akebia Therapeutics to Present at H.C. Wainwright Global Investment Conference. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the H.C. RHEA-AI. neutral.We are a fully integrated biopharmaceutical company. Our team works to address complications of kidney disease. We have both a commercially available medicine and a late stage oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), vadadustat.Vadadustat and other HIF-PHIs are based on Nobel Prize-winning science.8 hours ago · Akebia Therapeutics Stock Performance. NASDAQ AKBA opened at $0.40 on Tuesday. The firm has a 50 day simple moving average of $0.39 and a 200-day simple moving average of $1.14. AKBA Stock Forecast - Get a free AKBA stock predictions and find out whether you should buy or sell AKBA stock. The trend analysis tool will help you make a better prediction on the AKBA stock. Top Penny Stocks: Home: OTC Stocks: Stocks Under $2: Stocks Under $5: NASDAQ Penny Stocks:Complete Akebia Therapeutics Inc. stock information by Barron's. View real-time AKBA stock price and news, along with industry-best analysis. Investors need to pay close attention to Akebia Therapeutics (AKBA) stock based on the movements in the options market lately. AKBA: 7.04 (-3.16%) Corporate Donations to Support AKF Coronavirus Emergency Fund Help Provide a Lifeline to Low-Income Kidney Patients ACCESSWIRE - Tue Mar 31, 3:41PM CDT.The all-time high Akebia Therapeutics stock closing price was 29.17 on June 20, 2014. The Akebia Therapeutics 52-week high stock price is 3.63, which is 706.7% above the current share price. The Akebia Therapeutics 52-week low stock price is 0.30, which is 33.3% below the current share price. The average Akebia Therapeutics stock price for the ...Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 17 newly-hired employees options to purchase an aggregate of 129,000 shares of Akebia's common stock on January 31, 2022, as inducements material to each such employee's entering into ...In comparing Akebia Therapeutics Inc. (AKBA)'s stock with other industry players reveals that stock's current price change of 7.46% and that of -83.45% over the past 12 months is in competing position with that of Johnson & Johnson (JNJ) which saw its stock price fall by -0.57% in the last trading and went through an increase of 1.34% in past 12-month trading.Akebia Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl ...8 hours ago · Akebia Therapeutics Trading Down 5.4 %. NASDAQ:AKBA opened at $0.40 on Tuesday. The firm has a market cap of $73.78 million, a price-to-earnings ratio of -0.25 and a beta of 1.49. Akebia Therapeutics Inc. Annual stock financials by MarketWatch. View the latest AKBA financial statements, income statements and financial ratios. Institutions like mutual funds, pensions, and investment banks typically have large volumes of capital that they use to invest in stocks. Since institutions are tasked with maximizing returns for their investors, they typically spend a lot of time and effort understanding the company's revenue and profit prospects before they invest. Box: Pts ATR Field: High/Low Close. Reversal: Pts % ATR Field: High/Low Close. Size. 360 460 520 620 700 780 900 Portrait Landscape. Width: Height: Color Scheme. Default Blue Blue Gray Color Vision Impaired Dark Amber Dark Blue Dark Gray Dark Green Ice Graphite Mint Mohave Monochrome (Print) Murphy Night Rainier Rose Sand Sea Green Solar Spruce ... Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 17 newly-hired employees options to purchase an aggregate of 129,000 shares of Akebia's common stock on January 31, 2022, as inducements material to each such employee's entering into ...8 hours ago · Akebia Therapeutics Trading Down 5.4 %. NASDAQ:AKBA opened at $0.40 on Tuesday. The firm has a market cap of $73.78 million, a price-to-earnings ratio of -0.25 and a beta of 1.49. About Akebia Therapeutics, Inc. 245 FIRST STREET SUITE 1100, CAMBRIDGE, Massachusetts, 2142, United States +1 617 871-2098 https://www.akebia.com Akebia Therapeutics Inc is a biopharmaceutical...View institutional stock ownership, mutual fund ownership, and top individual ownership of AKEBIA THERAPEUTICS, INC. (AKBA).PR Newswire. SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Akebia Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 13, 2022 - (NASDAQ: AKBA ...Hello everyone, this is the first issue of The Biotech Report! In this issue of The Biotech Report, we will thoroughly examine Akebia Therapeutics: its partnerships, CEO, insider trading patterns, institutional holdings, and financials.Jul 12, 2022 · AKBA support price is $.38 and resistance is $.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKBA stock will trade within this expected range on the day. Because Finexy believes that no individual model can accurately predict the future direction of the price of a stock, we average buy and sell signals across multiple forward and backward looking indicators to determine whether the price is likely to go up or down over the short term. Akebia Therapeutics Inc. Annual stock financials by MarketWatch. View the latest AKBA financial statements, income statements and financial ratios.AKBA stock returns are also predicted based on historical data. According to our research, AKBA stock is a bad long-term investment. AKBA share price has been in a bear cycle for the past year. Akebia Therapeutics, Inc. stock trend is negative. Akebia Therapeutics company info.About the Akebia Therapeutics, Inc. stock forecast. As of 2022 June 29, Wednesday current price of AKBA stock is 0.351$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).. Akebia Therapeutics stock price has been showing a declining tendency so we believe that similar market segments were not very popular in the given period.Jul 25, 2022 · According to analyst projections, AKBA’s forecast low is $1.25 with $2.00 as the target high. To hit the forecast high, the stock’s price needs a -365.12% plunge from its current level, while the stock would need to soar -190.7% for it to hit the projected low. Akebia Therapeutics Inc. (AKBA) estimates and forecasts Akebia to Host Conference Call to Provide Business Update. CAMBRIDGE, Mass., July 26, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30 ...Ticker Symbol: AKBA: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: US Dollars: CIK Code: 0001517022: CUSIP Number: 00972D105: ISIN Number ...First Week of AKBA August 19th Options Trading Thursday, June 23, 10:52 AM. Noteworthy Wednesday Option Activity: AKBA, FSLR, LMND Wednesday, March 23, 3:22 PM. Notable Friday Option Activity: HCI, HLT, AKBA Friday, December 31, 3:48 PM. First Week of AKBA July 2022 Options Trading Friday, November 19, 2:17 PM. First Week of AKBA December 17th ...Akebia to Host Conference Call to Provide Business Update. CAMBRIDGE, Mass., July 26, 2022 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the second quarter ended June 30 ...Is AKBA a good stock to buy now? Prominent investors were in a bearish mood. The number of bullish hedge fund bets were trimmed by 7 recently. Akebia Therapeutics Inc (NASDAQ:AKBA) was in 18 hedge ...The total value of stock holdings in hedge funds' portfolios went down from $3.1 trillion at the end of December to $2.8 trillion at the end of March. This isn't a terribly large reduction in ...Akebia Therapeutics (AKBA) Gets a Hold Rating from H.C. Wainwright. H.C. Wainwright analyst Ed Arce maintained a Hold rating on Akebia Therapeutics (AKBA - Research Report) today and set a price target of $1.25. The company's shares closed last Friday at $0.45, close to its 52-week low of $0.35.Akebia Therapeutics, Inc. (AKBA) Performance Graph for POWR Ratings Akebia Therapeutics, Inc. (AKBA) Interactive Chart AKBA Chart by TradingViewFirst Week of AKBA August 19th Options Trading Thursday, June 23, 10:52 AM. Noteworthy Wednesday Option Activity: AKBA, FSLR, LMND Wednesday, March 23, 3:22 PM. Notable Friday Option Activity: HCI, HLT, AKBA Friday, December 31, 3:48 PM. First Week of AKBA July 2022 Options Trading Friday, November 19, 2:17 PM. First Week of AKBA December 17th ...Akebia Therapeutics (AKBA) soared more than 25% on Monday on high volume after UBS initiated coverage on the biopharmaceutical company with a "buy" rating and $28 price target. houses for sale in madisoncraftsman jack stands 3 tonbest vr games ps4jeff lynch appliances